# Effects of Pre- and Post-Supplementation of Taurine in the Hippocampus of a Gerbil Model of Transient Global Cerebral Ischemia

**Authors:** Md Shiblee Sadik Sabuj, Su-Cheol Han, Byung-Yong Park, Hyun-Jin Tae, Sung Min Nam

PMC · DOI: 10.3390/ijms27031341 · International Journal of Molecular Sciences · 2026-01-29

## TL;DR

This study shows that taurine supplementation before and after brain ischemia in gerbils protects neurons and reduces brain damage.

## Contribution

The study demonstrates that both pre- and post-treatment with taurine reduces ischemic brain injury in gerbils through multiple protective mechanisms.

## Key findings

- Taurine supplementation preserved neurons and reduced cell death in the hippocampus after ischemia.
- Taurine treatment reduced gliosis and mitigated oxidative stress and inflammation pathways.
- Taurine upregulated antioxidant and anti-apoptotic factors while downregulating harmful stress pathways.

## Abstract

Taurine is a free amino acid with various effects, such as developing the nervous system, an immune function, an antioxidative effect, enhancing muscle and cardiovascular function, and reducing fatigue. In this study, we investigated the effect of taurine supplementation on ischemic neuronal damage in the hippocampus of gerbils. Taurine (150 mg/kg) was orally administered to gerbils before and after induction of transient ischemia. Histologically, we examined surviving and degenerating neurons by neuronal nuclei immunostaining and fluoro-jade C (FJC) staining. Gliosis was morphologically confirmed by GFAP and Iba1 immunostaining. Compared to the ischemia and pre-treated gerbils, pre- and post-taurine supplementation was neuroprotective by maintaining higher number of mature NeuN-immunoreactive neurons and reducing neuronal death (FJC-stained cells) in the hippocampal CA1 region. Additionally, the ischemia-induced reactive astrocytosis and microgliosis was significantly mitigated by long-term taurine treatment in the gerbil hippocampus. Furthermore, we confirmed that pre- and post-taurine supplementation downregulated ischemia-mediated induction in the MAPK cascade, such as ERK, JNK, and p38, which are involved in oxidative stress, inflammation, apoptosis, and cell differentiation, and this treatment upregulated an ischemia-mediated reduction in antioxidants such as SOD2, GPX4, and anti-apoptotic factor Bcl-2 in the gerbil hippocampus. Pre- and post-taurine supplementation also downregulated again the ischemic injury-mediated activation of transcriptional factor NFkβ, an important gene expression regulator, especially in the inflammatory response, and pro-apoptotic factor Bax in the gerbil hippocampus. Our present results suggest that pre- and post-taurine supplementation has potential in neuroprotection against ischemia-induced neuronal death and glial activation by attenuating oxidative stress and apoptosis.

## Linked entities

- **Genes:** EPHB2 (EPH receptor B2) [NCBI Gene 2048], MAPK8 (mitogen-activated protein kinase 8) [NCBI Gene 5599], CRK (CRK proto-oncogene, adaptor protein) [NCBI Gene 1398], SOD2 (superoxide dismutase 2) [NCBI Gene 6648], GPX4 (glutathione peroxidase 4) [NCBI Gene 2879], BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596], BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581], NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790]
- **Chemicals:** taurine (PubChem CID 1123)

## Full-text entities

- **Genes:** RBFOX3 (RNA binding fox-1 homolog 3) [NCBI Gene 146713] {aka FOX-3, FOX3, HRNBP3, NEUN}, GPX4 (glutathione peroxidase 4) [NCBI Gene 2879] {aka GPx-4, GSHPx-4, MCSP, PHGPx, SMDS, snGPx}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, GFAP (glial fibrillary acidic protein) [NCBI Gene 2670] {aka ALXDRD}, AIF1 (allograft inflammatory factor 1) [NCBI Gene 199] {aka AIF-1, IBA1, IRT-1, IRT1}, SOD2 (superoxide dismutase 2) [NCBI Gene 6648] {aka GC1, GClnc1, IPO-B, IPOB, MNSOD, MVCD6}, MAPK14 (mitogen-activated protein kinase 14) [NCBI Gene 1432] {aka CSBP, CSBP1, CSBP2, CSPB1, EXIP, Mxi2}, BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581] {aka BCL2L4}, MAPK8 (mitogen-activated protein kinase 8) [NCBI Gene 5599] {aka JNK, JNK-46, JNK1, JNK1A2, JNK21B1/2, PRKM8}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}
- **Diseases:** fatigue (MESH:D005221), ischemic neuronal damage (MESH:D009410), Cerebral Ischemia (MESH:D002545), Gliosis (MESH:D005911), inflammation (MESH:D007249), ischemic injury (MESH:D017202), ischemia (MESH:D007511)
- **Chemicals:** jade C (-), Taurine (MESH:D013654), FJC (MESH:C534582), acid (MESH:D000143)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12898161/full.md

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12898161/full.md

## References

55 references — full list in the complete paper: https://tomesphere.com/paper/PMC12898161/full.md

---
Source: https://tomesphere.com/paper/PMC12898161